吉非替尼治疗晚期非小细胞肺癌疗效观察

目的:评价采用吉非替尼治疗化疗失败的局部晚期或转移性非小细胞肺癌(NSCLC)的疗效及不良反应。方法:42例化疗失败的局部晚期或转移性NSCLC患者予吉非替尼250mg每日1次口服直至病情进展或出现不可耐受的不良反应,评价近期疗效、生存期、生活质量及毒副反应。结果:CR1例、PR11例、SD18例、PD12例,有效率为28.57、临床受益率为71.43、中位无疾病进展时间为4个月、中位生存期为10个月、1年生存率为45.23;生活质量明显改善者占61.90;药物不良反应多为Ⅰ～Ⅱ度皮疹及腹泻。结论:吉非替尼应用于化疗失败的局部晚期或转移性NSCLC的二线或三线治疗疗效确切,不良反应轻微,而且可以明显改善患者的生活质量。

Efficacy of Gefitinib on patients with non-small cell lung cancer

Objective:To evaluate the efficacy of gefitinib on patients with locally advanced or metastatic non-small cell lung cancer(NSCLC) after failure of previous chemotherapy and explore its safety.Methods:A total of 42 pathologically-confirmed patients with locally advanced or metastatic NSCLC after failure of previous chemotherapy were enrolled.Gefitinib was orally administered 250mg once daily until disease progression or patients couldn't tolerate the toxicities.Evaluations were made about curative effects,survival time,quality of life and toxic reactions.Results:Among these 42 patients,CR 1(2.38%),PR 11(26.19%),SD 18(42.86%),PD 12(28.57%).The ORR was 28.57%,clinical benefit response was 71.43%,the mTTP was 4 months,the MST was 10 months,the OS was 45.23%,signs and quality of life improvement was 61.90%.The drug-related adverse reactions were skin rash(61.90%),and diarrhea(23.81%).The majority of adverse reactions were grade I or grade II.Interstitial lung disease was not found.Conclusions:Gefitinib is effective and safe in treating patients with locally advanced or metastatic NSCLC who need two or more line therapy.Furthermore it can remarkably improve patients'life quality.